Weight ManagementJuly 27, 2026·5 min read
By the CIRRUS Editorial Team — how we write and source this
Compounded GLP-1 drugs: what the safety data actually says
Shortages pushed patients toward compounded semaglutide and tirzepatide — the FDA's own adverse event data tells a specific, not generic, cautionary story.
During periods when branded GLP-1 supply couldn't meet demand, compounding pharmacies were legally permitted to produce copies under FDA's drug-shortage exemption — a narrower allowance than 'unregulated alternative' suggests, but one with real quality-control gaps compared to branded manufacturing. The FDA has since received adverse event reports tied specifically to dosing errors from compounded products, including overdoses from inconsistent concentration and vials that required patient self-measurement rather than pre-filled pens.
The clinical concern isn't the active ingredient itself — it's variability. A pre-filled branded pen delivers a validated, fixed dose; a compounded vial dosed with a syringe introduces a measurement step where errors compound over each injection. Salt forms of semaglutide used by some compounders (semaglutide sodium or acetate, versus the base compound in the approved drug) haven't undergone the same safety and efficacy review.
As branded supply has stabilized, the practical guidance from pharmacology specialists is consistent: compounded GLP-1s were a shortage-era stopgap, not a long-term substitute, and patients still using them should discuss transitioning back to an FDA-approved formulation with their prescriber.
This article is general health information, not medical advice, and doesn’t replace evaluation by your own physician. Talk to a doctor about anything specific to your own diagnosis or treatment.